Patents by Inventor Kerry S. Campbell

Kerry S. Campbell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES
    Publication number: 20240016957
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fr receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Application
    Filed: July 25, 2023
    Publication date: January 18, 2024
    Applicant: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
    Inventor: Kerry S. Campbell
  • GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES
    Publication number: 20230372545
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?,TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Application
    Filed: October 27, 2022
    Publication date: November 23, 2023
    Applicant: Fox Chase Cancer Center
    Inventor: Kerry S. Campbell
  • GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES
    Publication number: 20160067356
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD 16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?,TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Application
    Filed: August 26, 2015
    Publication date: March 10, 2016
    Inventor: Kerry S. Campbell
  • Genetically modified human natural killer cell lines
    Patent number: 9181322
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?,TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: November 10, 2015
    Assignee: Fox Chase Cancer Center
    Inventor: Kerry S. Campbell
  • Genetically modified human natural killer cell lines
    Patent number: 9150636
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: October 6, 2015
    Assignee: Fox Chase Cancer Center
    Inventor: Kerry S. Campbell
  • Genetically modified human natural killer cell lines
    Patent number: 8313943
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: November 20, 2012
    Assignee: Fox Chase Cancer Center
    Inventor: Kerry S. Campbell
  • GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES
    Publication number: 20100086996
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Application
    Filed: September 22, 2009
    Publication date: April 8, 2010
    Applicant: FOX CHASE CANCER CENTER
    Inventor: KERRY S. CAMPBELL
  • GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES
    Publication number: 20100086486
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Application
    Filed: September 22, 2009
    Publication date: April 8, 2010
    Applicant: FOX CHASE CANCER CENTER
    Inventor: KERRY S. CAMPBELL
  • Genetically modified human natural killer cell lines
    Patent number: 7618817
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: November 17, 2009
    Assignee: Fox Chase Cancer Center
    Inventor: Kerry S. Campbell
  • GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES
    Publication number: 20080247990
    Abstract: The invention provides a natural killer cell, NK-92, modified to express a CD16 receptor or an inhibitory killer cell immunoglobulin-like receptor (KIR) on a surface of the cell. In examples, the NK-92 cell is further modified to co-express an associated accessory signaling protein such as Fc?RI-? or TCR-?, chemokines, or cytokines such as interleukin-2 (IL-2) or interleukin-15 (IL-15). Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Application
    Filed: April 21, 2008
    Publication date: October 9, 2008
    Applicant: Fox Chase Cancer Center
    Inventor: Kerry S. Campbell